Review of quetiapine side effects

Journal of Clinical Psychiatry

Volumn 61, Issue SUPPL. 8, 2000, Pages 31-35

  Garver, David L ^a,b  

^a EAST TEXAS MEDICAL CENTER   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; CHLORPROMAZINE; CLOZAPINE; DIPHENHYDRAMINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; HISTAMINE H1 RECEPTOR; MUSCARINIC M1 RECEPTOR; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR;

CLINICAL TRIAL; CONSTIPATION; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; GALACTORRHEA; HUMAN; HYPERPROLACTINEMIA; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW; SCHIZOPHRENIA; TARDIVE DYSKINESIA; URINE RETENTION; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; DIBENZOTHIAZEPINES; HUMANS; PLACEBOS; PSYCHOTIC DISORDERS; RECEPTORS, ADRENERGIC, ALPHA; RECEPTORS, DOPAMINE; RECEPTORS, NEUROTRANSMITTER; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 0034102741     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. Arvanitis LA, Goldstein JM. The atypical profile of quetiapine is supported by its lack of sustained elevation of plasma prolactin concentrations. In: New Research Program and Abstracts of the 150th Annual Meeting of the American Psychiatric Association: May 18-20, 1997; San Diego, Calif. Abstract NR232:130
2. Arvanitis LA, Miller BG, and the Seroquel Trial 13 Study Group. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-2-6
3. Peuskens J, Link CGG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997;96:265-273
4. Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999;35: 51-68
5. Seroquel (quetiapine). Physicians' Desk Reference. Montvale, NJ: Medical Economics; 1999
6. Goldstein JM, Arvanitis LA. ICI 204,636 (Seroquel): a dibenzothiazepine atypical antipsychotic: review of preclinical pharmacology and highlights of Phase II clinical trials. CNS Drug Review 1995;1:50-73
7. Wong J, Ewing BJ, Jaskiw G, et al. Multiple-dose pharmacokinetics of 'Seroquel' (quetiapine) in elderly psychotic patients [abstract]. Schizophr Res 1997;24:199-200
8. McManus DQ, Arvanitis LA, Kowalcyk BB. Quetiapine, a novel antipsychotic: experience in elderly patients. J Clin Psychiatry 1999;60:292-298
9. Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997;54:549-557
10. Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. Seroquel Study Group. J Clin Psychopharmacol 1996;16:158-169
11. Hagberg G, Gefvert O, Bergstrom M, et al. N-[11C]methylspiperone PET. in contrast to [11C]raclopride, fails to detect D2 receptor occupancy by an atypical neuroleptic. Psychiatry Res 1998;30:147-160
12. Gefvert O, Bergstrom M, Langstrom B, et al. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology (Berl) 1998;135:119-126
13. Seeman P, Corbett R, Van Tol HH. Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology 1997;16:93-110